产品
编 号：F534786
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 947687-12-9
产品详情
生物活性：
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.
体内研究：
Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels.Animal Model:CB17SC-M scid-/- female mice (solid tumor xenografts model).
Dosage:1 mg/rat
Administration:Intraperitoneal injection; twice weekly for 6 weeks.
Result:Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression.
体外研究：
Cixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells.
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.
体内研究：
Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels.Animal Model:CB17SC-M scid-/- female mice (solid tumor xenografts model).
Dosage:1 mg/rat
Administration:Intraperitoneal injection; twice weekly for 6 weeks.
Result:Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression.
体外研究：
Cixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备